View in EDS

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology

Saved in:
Bibliographic Details
Title: A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Authors: Hyun Jin Baek, Jun Ho Ji, Jung Hun Kang, Joon Oh Park, Do Hyoung Lim, Sun Young Rha, Young Woong Won, Seung Tae Kim, Moon Jin Kim, Ho Yeong Lim, Jeeyun Lee, Soon Il Lee, Hee Kyung Ahn, In Gyu Hwang, Sung Yong Oh, Won Ki Kang, Young Suk Park, Jun Ho Yi, Taekyu Lim, Se Hoon Park, Chi Hoon Maeng, Hyo Song Kim, Kyung Eun Lee
Contributors: College of Medicine, Dept. of Internal Medicine, Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young-Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park, Kim, Hyo Song, Rha, Sun Young
Source: Cancer Res Treat
Publisher Information: Korean Cancer Association, 2016.
Publication Year: 2016
Subject Terms: Adult, Male, 0301 basic medicine, Histology, Stomach Neoplasms/ethnology, ErbB-2/metabolism, Receptor, ErbB-2, Stomach neoplasms, Antineoplastic Agents, Ethnic groups, Stomach Neoplasms/metabolism, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological/therapeutic use, Asian People, ErbB-2 receptor, Stomach Neoplasms, 80 and over, Humans, Stomach Neoplasms/drug therapy, Aged, Retrospective Studies, Aged, 80 and over, Asian Continental Ancestry Group, Stomach Neoplasms/pathology, Middle Aged, Trastuzumab, 3. Good health, Trastuzumab/therapeutic use, Original Article, Female, Receptor
Description: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
Document Type: Article
Other literature type
Language: English
ISSN: 2005-9256
1598-2998
DOI: 10.4143/crt.2015.155
Access URL: http://www.e-crt.org/upload/pdf/crt-2015-155.pdf
https://pubmed.ncbi.nlm.nih.gov/26323641
https://dspace.ewha.ac.kr/handle/2015.oak/231497?mode=full
https://www.ncbi.nlm.nih.gov/pubmed/?term=A+Retrospective+Analysis+for+Patients+with+HER2-Positive+Gastric+Cancer+Who+Were+Treated+with+Trastuzumab-Based+Chemotherapy%3A+In+the+Perspectives+of+Ethnicity+and+Histology
https://pubmed.ncbi.nlm.nih.gov/26323641/
https://core.ac.uk/display/159796064
https://e-sciencecentral.org/articles/SC000014568
http://www.e-crt.org/upload/pdf/crt-2015-155.pdf
Rights: CC BY NC
CC BY NC ND
Accession Number: edsair.doi.dedup.....154add0224b51ab53e6ec7662c92d01c
Database: OpenAIRE
Description
Abstract:While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
ISSN:20059256
15982998
DOI:10.4143/crt.2015.155